Serum miR-29a as a Marker of Multiple Myeloma
| Authors | |
|---|---|
| Year of publication | 2013 |
| Type | Article in Periodical |
| Magazine / Source | Leukemia & Lymphoma |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.3109/10428194.2012.704030 |
| Field | Oncology and hematology |
| Keywords | miR-29a; serum; microRNA; multiple myeloma |
| Attached files | |
| Description | MicroRNA (miRNA) are short non-coding RNA about 21-25 nucleotides long; they were reported to be involved in initiation and progression of solid tumors as well as hematological malignancies.Moreover, circulating miRNA were observed in serum. These circulating serum miRNA are very stable, resistant to RNAse treatment and differ between healthy subjects and patients with colorectal and lung cancer as well as diabetes. Nowadays, there are no specific markers for MM prediction. With the introduction of novel drugs and a very real possibility of targeted therapy in the near future, these markers are becoming increasingly important. If a specific marker was found in peripheral blood, it would be easily accessible and could be obtained at various time points of treatment and even in the time of remission for frequent monitoring. |
| Related projects: |
|